Why making Anthony Fauci the enemy will harm US public health for years - The Guardian

Read our review of Kramer/Fauci off Broadway, director Daniel Fish's adaptation of an infamous televised conversation between Dr. Anthony Fauci and Larry Kramer. SummaryKramer/Fauci is a staging of the 1993 C-SPAN debate between Anthony Fauci and Larry Kramer over the AIDS crisis and public healthThe show uses the verbatim transcript of the debate but stages it abstractly, including with a cloud of bubbles as a compelling symbol of the AIDS crisisThe show is recommended for those interested in the history of public health and how events like the AIDS crisis speak to modern-day events like the Covid pandemicFor most people, the name Anthony Fauci will likely inspire strong feelings and memories of Covid briefings. Larry Kramer is likewise a household name, remembered as a famed AIDS activist and sometimes controversial figure. Not many, though, know the pair were frenemies, who had a live conversation, including calls from viewers, on C-SPAN in 1993, 13 years into the HIV/AIDS crisis. It was a clash of titans, a fierce and fiery debate, and in Kramer/Fauci, director/adapter Daniel Fish (Oklahoma!) turns it into an equally fascinating piece of documentary theatre.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.